After a few quarters of "are they or aren't they?" uncertainty about Accuray's (ARAY) turnaround, I think this quarter was a significant step forward for the company. Product revenue and orders have both recovered to pre-merger levels and attitudes regarding the systems appear to have turned solidly to the positive. Valuation is becoming a trickier issue now and although the shares are not all that cheap anymore from a cash flow standpoint, the shares could still do well by the looser standards of med-tech investors.
Delivering The Goods In Fiscal Q2
Accuray reported 20% overall growth for the quarter, a nearly 18% beat relative to the average Wall Street guess. The relatively more predictable service revenue component...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: